Overview

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

Status:
COMPLETED
Trial end date:
2025-05-22
Target enrollment:
Participant gender:
Summary
This is a an open-label, fixed-sequence DDI study conducted in Chinese healthy subjects to investigate the effect of multiple oral doses of pimicotinib on the pharmacokinetics of fexofenadine , rosuvastatin and metformin . Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration. Approximately 38 healthy subjects will be enrolled to achieve 28 evaluable healthy subjects complete the study. Blood samples will be collected for PK analysis .
Phase:
PHASE1
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd